We administered recombinant human erythropoietin to 25 anemic patients with end-stage renal disease who were undergoing hemodialysis. The recombinant human erythropoietin was given intravenously three times weekly after dialysis, and transfusion requirements, hematocrit, ferrokinetics, and reticulocyte responses were monitored. Over a range of doses between 15 and 500 units per kilogram of body weight, dose-dependent increases in effective erythropoiesis were noted. At 500 units per kilogram, changes in the hematocrit of as much as 10 percentage points were seen within three weeks, and increases in ferrokinetics of three to four times basal values, as measured by erythron transferrin uptake, were observed. Of 18 patients receiving effective doses of recombinant human erythropoietin, 12 who had required transfusions no longer needed them, and in 11 the hematocrit increased to 35 percent or more. Along with the rise in hematocrit, four patients had an increase in blood pressure, and a majority had increases in serum creatinine and potassium levels. No organ dysfunction or other toxic effects were observed, and no antibodies to the recombinant hormone were formed. These results demonstrate that recombinant human erythropoietin is effective, can eliminate the need for transfusions with their risks of immunologic sensitization, infection, and iron overload, and can restore the hematocrit to normal in many patients with the anemia of end-stage renal disease.
This article has been cited by other articles:
Hamada, Y., Kono, T.-N., Moriguchi, Y., Higuchi, M., Fukagawa, M.
(2008). Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment. Nephrol Dial Transplant
23: 1886-1891
[Abstract][Full Text]
Fishbane, S., Besarab, A.
(2007). Mechanism of Increased Mortality Risk with Erythropoietin Treatment to Higher Hemoglobin Targets. CJASN
2: 1274-1282
[Abstract][Full Text]
Fares, F., Ganem, S., Hajouj, T., Agai, E.
(2007). Development of a Long-Acting Erythropoietin by Fusing the Carboxyl-Terminal Peptide of Human Chorionic Gonadotropin {beta}-Subunit to the Coding Sequence of Human Erythropoietin. Endocrinology
148: 5081-5087
[Abstract][Full Text]
Ehrenreich, H., Fischer, B., Norra, C., Schellenberger, F., Stender, N., Stiefel, M., Siren, A.-L., Paulus, W., Nave, K.-A., Gold, R., Bartels, C.
(2007). Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain
130: 2577-2588
[Abstract][Full Text]
Hsieh, M. M., Linde, N. S., Wynter, A., Metzger, M., Wong, C., Langsetmo, I., Lin, A., Smith, R., Rodgers, G. P., Donahue, R. E., Klaus, S. J., Tisdale, J. F.
(2007). HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood
110: 2140-2147
[Abstract][Full Text]
Sytkowski, A. J.
(2007). Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells. Sci Signal
2007: pe38-pe38
[Abstract][Full Text]
Lenga, I., Lok, C., Marticorena, R., Hunter, J., Dacouris, N., Goldstein, M.
(2007). Role of Oral Iron in the Management of Long-Term Hemodialysis Patients. CJASN
2: 688-693
[Abstract][Full Text]
Barany, P., Muller, H.-J.
(2007). Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. Nephrol Dial Transplant
22: iv10-iv18
[Abstract][Full Text]
Ingelfinger, J. R.
(2007). Through the Looking Glass: Anemia Guidelines, Vested Interests, and Distortions. CJASN
2: 415-417
[Full Text]
Fischer, M. A., Morris, C. A., Winkelmayer, W. C., Avorn, J.
(2007). Nononcologic Use of Human Recombinant Erythropoietin Therapy in Hospitalized Patients. Arch Intern Med
167: 840-846
[Abstract][Full Text]
Crawford, J.
(2007). Erythropoietin: High Profile, High Scrutiny. JCO
25: 1021-1023
[Full Text]
Bunn, H. F.
(2007). New agents that stimulate erythropoiesis. Blood
109: 868-873
[Abstract][Full Text]
Zumberg, M. S., Leissinger, C.
(2007). Acquired underproduction anemias. ASH-SAP
2007: 78-101
[Full Text]
Macdougall, I. C., Robson, R., Opatrna, S., Liogier, X., Pannier, A., Jordan, P., Dougherty, F. C., Reigner, B.
(2006). Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Chronic Kidney Disease. CJASN
1: 1211-1215
[Abstract][Full Text]
Santhanam, A. V. R., Smith, L. A., Nath, K. A., Katusic, Z. S.
(2006). In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries. Am. J. Physiol. Heart Circ. Physiol.
291: H781-H786
[Abstract][Full Text]
Eliopoulos, N., Gagnon, R. F., Francois, M., Galipeau, J.
(2006). Erythropoietin Delivery by Genetically Engineered Bone Marrow Stromal Cells for Correction of Anemia in Mice with Chronic Renal Failure. J. Am. Soc. Nephrol.
17: 1576-1584
[Abstract][Full Text]
Coleman, T. R., Westenfelder, C., Togel, F. E., Yang, Y., Hu, Z., Swenson, L., Leuvenink, H. G. D., Ploeg, R. J., d'Uscio, L. V., Katusic, Z. S., Ghezzi, P., Zanetti, A., Kaushansky, K., Fox, N. E., Cerami, A., Brines, M.
(2006). Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc. Natl. Acad. Sci. USA
103: 5965-5970
[Abstract][Full Text]
Steensma, D. P., Molina, R., Sloan, J. A., Nikcevich, D. A., Schaefer, P. L., Rowland, K. M. Jr, Dentchev, T., Novotny, P. J., Tschetter, L. K., Alberts, S. R., Hogan, T. F., Law, A., Loprinzi, C. L.
(2006). Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients With Cancer. JCO
24: 1079-1089
[Abstract][Full Text]
Messa, P., Nicolini, M. A., Cesana, B., Brezzi, B., Zattera, T., Magnasco, A., Moroni, G., Campise, M.
(2006). Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients. Nephrol Dial Transplant
21: 431-436
[Abstract][Full Text]
Kurzrock, R.
(2005). Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited. Clin. Cancer Res.
11: 1361-1367
[Abstract][Full Text]
Zotter, H, Robinson, N, Zorzoli, M, Schattenberg, L, Saugy, M, Mangin, P
(2004). Abnormally high serum ferritin levels among professional road cyclists. Br. J. Sports. Med.
38: 704-708
[Abstract][Full Text]
Beleslin-Cokic, B. B., Cokic, V. P., Yu, X., Weksler, B. B., Schechter, A. N., Noguchi, C. T.
(2004). Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood
104: 2073-2080
[Abstract][Full Text]
Sharma, R., Francis, D. P, Pitt, B., Poole-Wilson, P. A, Coats, A. J.S, Anker, S. D
(2004). Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J
25: 1021-1028
[Abstract][Full Text]
Fandrey, J.
(2004). Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am. J. Physiol. Regul. Integr. Comp. Physiol.
286: R977-R988
[Abstract][Full Text]
Roman, R. M.B., Lobo, P. I., Taylor, R. P., Goodkin, D. A., LaBrecque, J., Powers, K. L., Bolton, W. K.
(2004). Prospective Study of the Immune Effects of Normalizing the Hemoglobin Concentration in Hemodialysis Patients Who Receive Recombinant Human Erythropoietin. J. Am. Soc. Nephrol.
15: 1339-1346
[Abstract][Full Text]
Jadoul, M., Vanrenterghem, Y., Foret, M., Walker, R., Gray, S. J.
(2004). Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant
19: 898-903
[Abstract][Full Text]
Dar Santos, A. E, Shalansky, K. F, Jastrzebski, J. P
(2003). Management of Anemia in Erythropoietin-Resistant Hemodialysis Patients. The Annals of Pharmacotherapy
37: 1768-1773
[Abstract][Full Text]
Krisper, P., Quehenberger, F., Schneditz, D., Holzer, H., Polaschegg, H. D.
(2003). Prediction of time-averaged concentration of haemoglobin in haemodialysis patients. Nephrol Dial Transplant
18: 2082-2087
[Abstract][Full Text]
Brimble, K. S., Rabbat, C. G., McKenna, P., Lambert, K., Carlisle, E. J.
(2003). Protocolized Anemia Management with Erythropoietin in Hemodialysis Patients: A Randomized Controlled Trial. J. Am. Soc. Nephrol.
14: 2654-2661
[Abstract][Full Text]
Ng, T, Marx, G, Littlewood, T, Macdougall, I
(2003). Recombinant erythropoietin in clinical practice. Postgrad. Med. J.
79: 367-376
[Abstract][Full Text]
Macdougall, I. C., Matcham, J., Gray, S. J.
(2003). Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant
18: 576-581
[Abstract][Full Text]
Chuang, C.-L., Liu, R.-S., Wei, Y.-H., Huang, T.-P., Tarng, D.-C.
(2003). Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant
18: 370-377
[Abstract][Full Text]
Fisher, J. W.
(2003). Erythropoietin: Physiology and Pharmacology Update. Exp. Biol. Med.
228: 1-14
[Abstract][Full Text]
Semba, R. D., Juul, S. E.
(2002). Erythropoietin in Human Milk: Physiology and Role in Infant Health. J Hum Lact
18: 252-261
[Abstract]
Coladonato, J. A., Frankenfield, D. L., Reddan, D. N., Klassen, P. S., Szczech, L. A., Johnson, C. A., Owen, W. F. Jr.
(2002). Trends in Anemia Management among US Hemodialysis Patients. J. Am. Soc. Nephrol.
13: 1288-1295
[Abstract][Full Text]
Eschbach, J. W.
(2002). Anemia Management in Chronic Kidney Disease: Role of Factors Affecting Epoetin Responsiveness. J. Am. Soc. Nephrol.
13: 1412-1414
[Full Text]
Beholz, S., Liu, J., Thoelke, R., Spiess, C, Konertz, W.
(2001). Use of desmopressin and erythropoietin in an anaemic Jehovah's Witness patient with severely impaired coagulation capacity undergoing stentless aortic valve replacement. Perfusion
16: 485-489
[Abstract]
YazicioGlu, L., Eryilmaz, S., Sirlak, M., Inan, M. B., Aral, A., Tasoz, R., Eren, N. T., Kaya, B., Akalin, H.
(2001). Recombinant human erythropoietin administration in cardiac surgery. J. Thorac. Cardiovasc. Surg.
122: 741-745
[Abstract][Full Text]
Karpati, I., Seres, I., Matyus, J., Ben, T., Paragh, G., Varga, Z., , G. K.
(2001). Which parameters affect cytosolic free calcium in polymorphonuclear leukocytes of haemodialysis patients?. Nephrol Dial Transplant
16: 1409-1415
[Abstract][Full Text]
Tessitore, N., Solero, G. P., Lippi, G., Bassi, A., Faccini, G. B., Bedogna, V., Gammaro, L., Brocco, G., Restivo, G., Bernich, P., Lupo, A., Maschio, G.
(2001). The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant
16: 1416-1423
[Abstract][Full Text]
Dalle, B., Henri, A., Rouyer-Fessard, P., Bettan, M., Scherman, D., Beuzard, Y., Payen, E.
(2001). Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood
97: 3776-3782
[Abstract][Full Text]
Akimoto, T., Kusano, E., Fujita, N., Okada, K., Saito, O., Ono, S., Ando, Y., Homma, S., Saito, T., Asano, Y.
(2001). Erythropoietin modulates angiotensin II- or noradrenaline-induced Ca2+ mobilization in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant
16: 491-499
[Abstract][Full Text]
Drueke, T. B., Lameire, N.
(2001). Report from the Editorial Office. Nephrol Dial Transplant
16: 29-31
[Full Text]
Movilli, E., Carlo Cancarini, G., Zani, R., Camerini, C., Sandrini, M., Maiorca, R.
(2001). Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant
16: 111-114
[Abstract][Full Text]
Ness, P. M.
(2000). Transfusion Medicine: An Overview and Update. Clin. Chem.
46: 1270-1276
[Abstract][Full Text]
Goodnough, L. T., Skikne, B., Brugnara, C.
(2000). Erythropoietin, iron, and erythropoiesis. Blood
96: 823-833
[Abstract][Full Text]
IKEGAYA, N., YAMAMOTO, T., TAKESHITA, A., WATANABE, T., YONEMURA, K., MIYAJI, T., OHISHI, K., FURUHASHI, M., MARUYAMA, Y., HISHIDA, A.
(2000). Elevated Erythropoietin Receptor and Transforming Growth Factor-{beta}1 Expression in Stenotic Arteriovenous Fistulae Used for Hemodialysis. J. Am. Soc. Nephrol.
11: 928-935
[Abstract][Full Text]
Bellone, G., Rollino, C., Borsa, S., Ferrero, I., Martina, G., Carbone, A., Mareschi, K., Quarello, F., Piccoli, G., Emanuelli, G., Matera, L.
(2000). Association Between Elevated Prolactin Levels and Circulating Erythroid Precursors in Dialyzed Patients. Exp. Biol. Med.
223: 367-371
[Abstract][Full Text]
BESARAB, A., AMIN, N., AHSAN, M., VOGEL, S. E., ZAZUWA, G., FRINAK, S., ZAZRA, J. J., ANANDAN, J. V., GUPTA, A.
(2000). Optimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients. J. Am. Soc. Nephrol.
11: 530-538
[Abstract][Full Text]
ROOB, J. M., KHOSCHSORUR, G., TIRAN, A., HORINA, J. H., HOLZER, H., WINKLHOFER-ROOB, B. M.
(2000). Vitamin E Attenuates Oxidative Stress Induced by Intravenous Iron in Patients on Hemodialysis. J. Am. Soc. Nephrol.
11: 539-549
[Abstract][Full Text]
Kaushansky, K.
(2000). Blood: New designs for a new millennium. Blood
95: 1-6
[Full Text]
Kiyama, H., Ohshima, N., Imazeki, T., Yamada, T.
(1999). Autologous blood donation with recombinant human erythropoietin in anemic patients. Ann. Thorac. Surg.
68: 1652-1656
[Abstract][Full Text]
MACDOUGALL, I. C., GRAY, S. J., ELSTON, O., BREEN, C., JENKINS, B., BROWNE, J., EGRIE, J.
(1999). Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients. J. Am. Soc. Nephrol.
10: 2392-2395
[Abstract][Full Text]
Ebert, B. L., Bunn, H. F.
(1999). Regulation of the Erythropoietin Gene. Blood
94: 1864-1877
[Full Text]
XIA, H., EBBEN, J., MA, J. Z., COLLINS, A. J.
(1999). Hematocrit Levels and Hospitalization Risks in Hemodialysis Patients. J. Am. Soc. Nephrol.
10: 1309-1316
[Abstract][Full Text]
Pierelli, L., Perillo, A., Greggi, S., Salerno, G., Panici, P. B., Menichella, G., Fattorossi, A., Leone, G., Mancuso, S., Scambia, G.
(1999). Erythropoietin Addition to Granulocyte Colony-Stimulating Factor Abrogates Life-Threatening Neutropenia and Increases Peripheral-Blood Progenitor-Cell Mobilization After Epirubicin, Paclitaxel, and Cisplatin Combination Chemotherapy: Results of a Randomized Comparison. JCO
17: 1288-1288
[Abstract][Full Text]
Savarese, D., Waitkus, H., Stewart, F. M., Callery, M.
(1999). Bloodless Medicine and Surgery. J Intensive Care Med
14: 20-33
Lejnieks, D. V., Ramesh, N., Lau, S., Osborne, W. R.A.
(1998). Stomach Implant for Long-Term Erythropoietin Expression in Rats. Blood
92: 888-893
[Abstract][Full Text]
Henry, D. H.
(1998). Supplemental Iron: A Key to Optimizing the Response of Cancer-Related Anemia to rHuEPO?. The Oncologist
3: 275-278
[Abstract][Full Text]
KEATING, E. M.
(1998). Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Current Options and Approaches for Blood Management in Orthopaedic Surgery*{{dagger}}. JBJS
80: 750-62
[Full Text]
Sytkowski, A. J., Lunn, E. D., Davis, K. L., Feldman, L., Siekman, S.
(1998). Human erythropoietin dimers with markedly enhanced in vivo activity. Proc. Natl. Acad. Sci. USA
95: 1184-1188
[Abstract][Full Text]
Kato, M., Miura, K., Kamiyama, H., Okazaki, A., Kumaki, K., Kato, Y., Sugiyama, Y.
(1998). Pharmacokinetics of Erythropoietin in Genetically Anemic Mice. Drug Metab. Dispos.
26: 126-131
[Abstract][Full Text]
Kato, M., Kamiyama, H., Okazaki, A., Kumaki, K., Kato, Y., Sugiyama, Y.
(1997). Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats. J. Pharmacol. Exp. Ther.
283: 520-527
[Abstract][Full Text]
Goodnough, L. T., Monk, T. G., Andriole, G. L.
(1997). Erythropoietin Therapy. NEJM
336: 933-938
[Full Text]
Sowade, O., Warnke, H., Scigalla, P., Sowade, B., Franke, W., Messinger, D., Gross, J.
(1997). Avoidance of Allogeneic Blood Transfusions by Treatment With Epoetin Beta (Recombinant Human Erythropoietin) in Patients Undergoing Open-Heart Surgery. Blood
89: 411-418
[Abstract][Full Text]
SPARLING, E. A., NELSON, C. L., LAVENDER, R., SMITH, J.
(1996). The Use of Erythropoietin in the Management of Jehovah's Witnesses Who Have Revision Total Hip Arthroplasty. JBJS
78: 1548-52
[Abstract][Full Text]
Klahr, S.
(1996). Anemia, Dialysis, and Dollars. NEJM
334: 461-463
[Full Text]
Robertson, J. S., Graves, J., Himmelstein, D. U., Woolhandler, S., Stark, P., Goodkin, D. A., Iglehart, J. K., Greer, J. W.
(1993). The End Stage Renal Disease Program. NEJM
329: 139-141
[Full Text]
Koury, M. J.
(1993). Investigating Erythropoietin Resistance. NEJM
328: 205-206
[Full Text]
Rodgers, G. P., Dover, G. J., Uyesaka, N., Noguchi, C. T., Schechter, A. N., Nienhuis, A. W.
(1993). Augmentation by Erythropoietin of the Fetal-Hemoglobin Response to Hydroxyurea in Sickle Cell Disease. NEJM
328: 73-80
[Abstract][Full Text]
Campos, A., Garin, E. H.
(1992). Therapy of Renal Anemia in Children and Adolescents with Recombinant Human Erythropoietin (rHuEPO). CLIN PEDIATR
31: 94-99
[Abstract]
Hanna, J. D., Foreman, J. W., Chan, J. C.M.
(1991). Chronic Renal Insufficiency in Infants and Children. CLIN PEDIATR
30: 365-384
Finley, R. S.
(1991). Overview of Biotechnology in Health Care. Journal of Pharmacy Practice
4: 80-86
Kickler, T.
(1989). How Safe Are Transfusions? Measures to Increase Safety. J Intensive Care Med
4: 93-94
Sachs, L
(1987). The molecular control of blood cell development. Science
238: 1374-1379
[Abstract]
Clark, S., Kamen, R
(1987). The human hematopoietic colony-stimulating factors. Science
236: 1229-1237
[Abstract]
Kolata, G
(1987). Clinical promise with new hormones. Science
236: 517-519
Previous
